A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies.

Trial Profile

A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs CLR 1404 I-131 (Primary)
  • Indications Advanced breast cancer; Colon cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Soft tissue sarcoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 23 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top